AliveX Biotech Showcases AI-Driven Computational Modeling to Replace Animal Testing at 2025 Future Healthcare 100 Summit

In recent years, the speed and quality of global innovative drug development have placed higher demands on companies. The traditional reliance on animal testing faces challenges such as limitations in model extrapolation, long cycles, and high costs. Particularly in the fields of immune-related diseases and novel antibody drugs, it is crucial to efficiently advance clinical translation while meeting the stringent requirements for scientific rigor and human relevance imposed by regulators both in China and internationally.International regulatory agencies such as the FDA and EMA are actively promoting the application of New Alternative Methods (NAMs), encouraging companies to adopt alternative solutions like mechanistic modeling and in vitro testing, providing new opportunities for reducing R&D costs, improving efficiency, and enhancing compliance levels.

Ms. Wenwen Wen pointed out that, with the continuous improvement and implementation of model-driven drug development policies by regulatory agencies worldwide, New Approach Methodologies (NAMs) are gradually becoming a key driving force for innovative drug development.By deeply integrating large models, mechanistic modeling, and high-dimensional biological data, we can predict drug safety and efficacy in a more scientific and efficient manner, optimize overall drug development strategies, thereby reducing reliance on animal testing, lowering R&D costs, shortening development cycles, and better aligning with the policy orientations of regulatory agencies such as the FDA, effectively improving the approval efficiency for new drug applications.These innovative applications will also help forward-looking Chinese biopharmaceutical companies gain more initiative and development opportunities in the global market.

AliveX Biotech's pharmacology modeling expert team has over 40 years of profound experience and service case accumulation in the fields of pharmacology modeling simulation, QSP, and pharmacometrics.With full-process, systematic professional services,Become an important partner for global biopharmaceutical companies in promoting non-animal methods, obtaining regulatory exemptions for animal testing, accelerating approval processes, saving substantial R&D costs, and enhancing R&D success rates and compliance standards.Help enterprises achieve outstanding breakthroughs in clinical outcomes for their drug pipelines, lead the clinical approval process for similar drugs, and seize the global market opportunities.

AliveX Biotech boasts a world-leading AI + multi-omics technology platform, dedicated to providing end-to-end premium R&D solutions in the biomedicine research and development field, including AI bio-computation, model-guided drug discovery, multi-omics central laboratory services, and more. The company consistently adheres to the core values of "cutting-edge, innovation, professionalism, and rigor," driven by AI + multi-omics technology. In disease areas such as oncology and immunology, AliveX Biotech offers mechanistic research on diseases and drugs, discovery and evaluation of biomarkers and targets, pharmacological and pharmacodynamic assessments, optimization of clinical trial protocols, and precision medicine strategies, enhancing the efficiency and success rate of R&D. AliveX Biotech has an internationally top-tier interdisciplinary team of academician professors and experts, with expertise spanning AI, biology, omics technologies, pharmacological digital twins, and more, backed by robust global service capabilities.